Swedish Orphan Biovitrum AB

SOBI

Equity

ISIN SE0000872095 / Valor 2676862

NASDAQ Nordic Exchange Stockholm, Equities (2024-11-20)

SEK 289.80-4.04%

Swedish Orphan Biovitrum AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company focused on developing and providing innovative therapies for rare diseases. The company's mission is to improve the lives of people with rare diseases by offering specialized treatments and support services. Sobi's portfolio includes a range of products for various rare diseases, with a strong emphasis on research and development to address unmet medical needs in the rare disease community. Through strategic partnerships and collaborations, Sobi aims to expand its reach and impact in the global rare disease market.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Swedish Orphan Biovitrum AB reported a total revenue of SEK 6,844 million for Q2 2024, reflecting a significant increase from the previous quarter. This growth was driven by strong performance across its haematology and immunology segments.

Haematology Segment Performance

The haematology segment saw notable growth, with Elocta sales increasing by 14% and Alprolix sales rising by 8% in Q2 2024. This was attributed to an increase in the number of patients, geographic expansion, and favorable phasing impacts, although some regions experienced continued price pressure.

Immunology Segment Performance

In the immunology segment, Gamifant sales grew by 4% and Kineret sales increased by 11% in Q2 2024. The growth was driven by increased demand across all regions, higher average dosing, and beneficial impacts from order phasing.

Profit and Earnings

Swedish Orphan Biovitrum AB reported an adjusted gross profit of SEK 4,166 million for Q2 2024, a 20% increase from the previous quarter. The adjusted EBITA margin was reported to be in the mid-30s percentage of revenue, indicating strong profitability.

Outlook for 2024

For the full year 2024, Swedish Orphan Biovitrum AB anticipates revenue growth by a low double-digit percentage at constant exchange rates. The company also expects the adjusted EBITA margin to remain in the mid-30s percentage of revenue, reflecting continued strong financial performance.

Summarized from source with an LLMView Source

Key figures

19.9%1Y

33.3%3Y

90.8%5Y

Performance

28.4%1Y

32.5%3Y

36.7%5Y

Volatility